STOCK TITAN

Inogen Inc - INGN STOCK NEWS

Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.

Inogen Inc. (INGN) is a pioneering medical technology company committed to enhancing the quality of life for supplemental oxygen users. Founded in 2001, Inogen emerged from a personal story of necessity and innovation. The company's mission began when Mae, the grandmother of one of the founders, was prescribed oxygen therapy, highlighting the need for more user-friendly and portable oxygen solutions. You can learn more about Mae's story here.

Inogen aims to revolutionize oxygen therapy technology, striving to keep pace with the active lifestyles of patients who rely on oxygen to lead fulfilling lives. The company estimates that over 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy.

The company's flagship product, the Inogen One system, is a compact, lightweight, and travel-approved portable oxygen concentrator designed to liberate patients from the constraints of heavy tanks, frequent refills, and stationary systems. This innovation provides patients with the freedom and independence to live their lives by moments, not by the minutes left in an oxygen tank.

Inogen's products and services are sold through various channels, including home medical equipment providers, distributors, large gas companies, and home oxygen providers. The company also rents its products directly to patients, generating the majority of its revenue within the United States.

Inogen's commitment to continuous improvement is evident in its ongoing projects and recent achievements. The company constantly works toward refining its product offerings and expanding its reach to benefit more patients globally.

Rhea-AI Summary

Inogen, Inc. reported Q1 2022 total revenue of $80.4 million, down 7.5% year-over-year due to supply chain issues. However, revenue increased 5.2% sequentially from Q4 2021. Domestic direct-to-consumer sales rose 12.2% to $34.4 million, while business-to-business sales dropped 83.4% to $5.1 million. International business-to-business revenue surged 77.7% to $27.9 million. A net loss of $14.2 million was reported, with adjusted loss per diluted share of $0.39. The company did not provide revenue guidance for 2022, citing ongoing market uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
-
Rhea-AI Summary

Sommetrics, focused on enhancing sleep health, reported key Q1 2022 achievements, notably advancing clinical activities for FDA clearance of aerSleep® II, a non-invasive treatment for obstructive sleep apnea. The six-month SUPRA pivotal trial is ongoing at various U.S. sleep centers, with promising safety data. Recent patent approvals in the U.S. and Japan bolster its intellectual property, totaling 36 patents. The company is targeting $16 million in its Series C financing, raising $11 million so far. Scott Wilkinson, former Inogen CEO, has been appointed as Advisor to guide aerSleep® II's market entry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
-
Rhea-AI Summary

Inogen, Inc (NASDAQ: INGN) announced its first quarter 2022 financial results will be released after market close on May 5, 2022. The company will host a conference call at 2:00pm PT / 5:00pm ET to discuss these results. Interested parties can listen by calling (877) 841-3961 for domestic or (201) 689-8589 for international access. A replay will be available from 4:00pm PT on the same day until 4:00pm PT on May 19, 2022. Access to the webcast will also be provided via Inogen's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
Rhea-AI Summary

Inogen, a medical technology company specializing in homecare respiratory products, announced its participation in the 21st Annual Needham Virtual Healthcare Conference. CEO Nabil Shabshab and CFO Kristin Caltrider are set to present on April 13, 2021, at 12:45 p.m. ET. Interested parties can access the live webcast on Inogen's Investor Relations page. The presentation will be available for replay for 90 days following the event. Inogen is known for developing portable oxygen concentrators aimed at patients with chronic respiratory conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN) announced participation in the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2022, at 4:30 p.m. ET. The company's President and CEO, Nabil Shabshab, and CFO, Kristin Caltrider, will present at the event. A webcast will be available on the Inogen Investor Relations website, with a replay accessible for 90 days post-presentation. Inogen specializes in developing and marketing portable oxygen concentrators for chronic respiratory conditions, aiming to enhance homecare solutions for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.79%
Tags
none
-
Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN) appointed Kristin Caltrider as EVP & Chief Financial Officer, effective March 21, 2022, succeeding interim CFO Mike Sergesketter. Nabil Shabshab, CEO, expressed confidence in Caltrider's proven experience in healthcare financial operations. Caltrider previously served as Vice President of Finance at Quidel Corporation. She aims to leverage Inogen's strong talent base and strategic plan for sustainable growth. The transition aims for smooth continuity as the company seeks to enhance its position in the respiratory care MedTech sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN) reported Q4 2021 total revenue of $76.4 million, a 3.3% year-over-year increase. Domestic direct-to-consumer revenue rose 23.3% to $33.0 million, while rental revenue surged 39.4% to $13.0 million. Full-year revenue reached $358.0 million, up 16.1% from 2020. Adjusted EBITDA for Q4 was ($0.5 million) with a net loss of $22.9 million. Supply chain challenges, especially regarding semiconductor availability, are expected to impact operations in 2022. The company anticipates mid-single-digit revenue growth for the year, with negative EBITDA and operating losses projected for Q1 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
-
Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN) will release its fourth quarter 2021 financial results after market close on February 24, 2022. A conference call is scheduled for 2:00 PM PT / 5:00 PM ET to discuss the results. Interested parties can listen by calling (877) 841-3961 for domestic and (201) 689-8589 for international callers. A replay will be available starting at 4:00 PM PT on the same day until March 10, 2022. More information is accessible via their Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
-
Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN) announced preliminary Q4 2021 revenue between $75.9 million and $76.9 million, a 2.6% to 3.9% increase from Q4 2020. Full-year revenue for 2021 is expected to be between $357.5 million and $358.5 million, marking a 15.9% to 16.2% increase year-over-year. The revenue growth was supported by higher average selling prices and demand, despite challenges from semiconductor supply constraints. Inogen faces a potential halt in EU sales due to regulatory changes expected by May 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.02%
Tags
none
Rhea-AI Summary

Gelesis has appointed Ali Bauerlein to its Board of Directors as it prepares for a public listing. Bauerlein, with a successful track record in scaling companies, previously co-founded Inogen (NASDAQ: INGN) and led it to over $300M in revenue. Gelesis aims to expand the commercialization of its product Plenity, a weight management solution. The company is also moving forward with its merger with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR), with the registration statement approved by the SEC. The combined entity's shares will trade under the ticker GLS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
management

FAQ

What is the current stock price of Inogen (INGN)?

The current stock price of Inogen (INGN) is $8.71 as of October 31, 2024.

What is the market cap of Inogen (INGN)?

The market cap of Inogen (INGN) is approximately 205.9M.

What does Inogen Inc. do?

Inogen Inc. develops and manufactures portable oxygen concentrators to deliver oxygen therapy for patients with chronic respiratory conditions.

What is Inogen's flagship product?

Inogen's flagship product is the Inogen One system, a compact and lightweight portable oxygen concentrator.

How does Inogen sell its products?

Inogen sells its products through home medical equipment providers, distributors, large gas companies, and home oxygen providers. They also rent products directly to patients.

Where does Inogen generate most of its revenue?

Inogen generates the majority of its revenue in the United States.

How many patients use oxygen therapy according to Inogen?

Inogen estimates that more than 2.5 million patients in the United States and over 4.5 million patients worldwide use oxygen therapy.

What makes Inogen's products stand out?

Inogen's products, like the Inogen One system, are designed to be compact, lightweight, and travel-approved, freeing patients from heavy tanks and stationary systems.

What is the mission of Inogen Inc.?

Inogen's mission is to improve the quality of life for supplemental oxygen users by providing innovative and user-friendly oxygen therapy solutions.

Who inspired the founding of Inogen?

Inogen was inspired by Mae, the grandmother of one of the founders, who was prescribed oxygen therapy and needed a more convenient solution.

Where can I learn more about Inogen's history?

You can learn more about Inogen's history and inspiration behind its founding on their website at http://www.inogen.com/about-inogen/meet-mae/.

What is Inogen Inc.'s stock symbol?

Inogen Inc. is publicly traded with the stock symbol INGN.

Inogen Inc

Nasdaq:INGN

INGN Rankings

INGN Stock Data

205.88M
23.72M
1.79%
95.9%
3.93%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
GOLETA